Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPN 2853

Next Previous
Drug Profile

OPN 2853

Alternative Names: OPN-2853; PLX-2853

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Daiichi Sankyo Company; Opna Bio; University of Birmingham
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myelofibrosis
  • Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Gynaecological cancer; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 09 Dec 2024 Interim adverse events and efficacy data from the phase-I PROMise trial in Myelofibrosis released by Opna Bio ,
  • 02 Feb 2024 OPN 2853 is available for licensing as of 24 Jan 2024 (https://www.opnabio.com/pipeline/)
  • 14 Apr 2023 Efficacy and adverse event data from phase Ib/IIa trial in Ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top